KMC Speciality Hospitals FY26 Results: Revenue ₹305.77 Cr

Stock snapshot and the key update

KMC Speciality Hospitals (India) Ltd (BSE: 524520) was in focus after disclosures around its board meeting held on May 29, 2026. The company’s share price was ₹119.3 as of June 15, 2026, with the screen showing a move of -₹0.65 (-0.54%). Separately, the risk check summary in the provided data flagged: “No risks detected for 524520 from our risk checks.”

The main developments were twofold. First, the board considered and approved the audited financial results for the quarter and year ended March 31, 2026. Second, the board approved an expansion-linked decision involving land purchase and a new hospital project.

Board meeting: schedule, agenda, and timing

KMC Speciality Hospitals informed BSE that its Board of Directors would meet on May 29, 2026 to consider and approve audited financial results for the quarter and financial year ended March 31, 2026. The company positioned the meeting as important for finalising its annual financial performance.

As per the outcome details provided, the board meeting commenced at 10:30 AM and concluded at 11:35 AM on May 29, 2026. The filing also referenced the approval of standalone audited financial results and the availability of the auditors’ report.

FY26 audited numbers: revenue and profit growth

In the board meeting outcome, KMC Speciality Hospitals reported FY26 standalone revenue of ₹305.77 crore, up 32.03% year-on-year. Net profit for FY26 was ₹46.73 crore, up 118.1% year-on-year.

The growth rates were highlighted alongside the audited results. The update in the provided text also reiterated the FY26 revenue level in Hindi commentary, consistent with the disclosed figure.

Q4 FY26 performance and EPS movement

For Q4 FY26, the company disclosed revenue of ₹82.25 crore and net profit of ₹14.63 crore. In addition, the dataset includes a “Total Income” figure in lakh terms for the quarter, which translates to crore values for easier comparison.

Total Income for Q4 FY26 was reported at ₹84.1588 crore (₹8,415.88 lakh). For Q3 FY26, Total Income was ₹83.1858 crore (₹8,318.58 lakh), implying a quarter-on-quarter increase of 1.17% as stated.

On per-share profitability, Basic and Diluted EPS for Q4 FY26 was ₹0.90. This was higher than ₹0.84 in Q3 FY26 and ₹0.27 in Q4 FY25, as per the provided details.

Cash flow, cash balance, and long-term debt

The provided information also included operating cash flow and balance sheet indicators. Operating cash flow rose from ₹57.50 crore in FY25 to ₹79.10 crore in FY26.

Cash balance at the end of FY26 was stated to have increased from ₹9.19 crore to ₹50 crore. Long-term debt was indicated as declining from ₹72.30 crore to ₹61.40 crore over the same period.

These data points were presented in the commentary as supporting evidence that the performance was not only “in accounting books” but also reflected in cash generation.

Expansion plan: ₹62.50 crore land purchase for 300 beds

A key board decision highlighted in the text was approval to purchase one acre of land for construction of a new hospital. The land cost mentioned was ₹62.50 crore.

The project is linked to an approximately 300-bed addition, with the new hospital planned on the acquired land. The location in the provided text is referenced as “Tirchi,” commonly used for Tiruchirappalli, and the decision was framed as an expansion move to add capacity.

What the filings say about compliance and audits

The dataset references the auditors’ report being available and that the audited results were approved by the board. It also includes a separate historical reference to a May 28, 2025 board meeting outcome where the company disclosed standalone audited financial results for the quarter and year ended March 31, 2025, along with an auditors’ report and a declaration regarding an unmodified opinion under SEBI (LODR) Regulations.

For May 29, 2026, the central disclosure point remains that the board met to approve the audited numbers for Q4 and the full year ended March 31, 2026.

Key numbers at a glance

Market impact: what changed after May 29 disclosures

The disclosures bundled operating performance and capital allocation decisions in one outcome. FY26 growth in revenue and profit, the rise in operating cash flow, and the fall in long-term debt provide specific operating and balance sheet markers investors track.

At the same time, the ₹62.50 crore land purchase approval and the 300-bed hospital plan add a tangible expansion element to the update. The stock quote in the provided data shows the share price at ₹119.3 as of June 15, 2026, with a small negative move of -0.54% on the screen at that point.

Why the board decisions matter

Audited results are a formal checkpoint because they finalise annual numbers and typically anchor how investors compare performance across years. The FY26 figures provided include both growth rates and absolute amounts, allowing readers to see scale and momentum in one place.

The expansion decision is also material because it ties a specific outlay, ₹62.50 crore, to a defined capacity target of around 300 beds. For hospital operators, bed capacity is a core operational lever, and board approvals for land and construction are among the earliest formal steps that indicate intent to add capacity.

Conclusion and what to watch next

KMC Speciality Hospitals’ May 29, 2026 board meeting closed with approval of audited FY26 results showing revenue of ₹305.77 crore and net profit of ₹46.73 crore, alongside Q4 revenue of ₹82.25 crore and profit of ₹14.63 crore. The company also approved a ₹62.50 crore land purchase for a new ~300-bed hospital.

The next set of confirmed milestones to watch will be subsequent disclosures around execution of the land purchase and further project updates related to the proposed hospital construction, as and when the company files them with the exchanges.